Veerle I.j. Bossuyt, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 36 | 2023 | 20059 | 1.400 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 7 | 2018 | 1055 | 1.300 |
Why?
|
| Neoadjuvant Therapy | 12 | 2020 | 2567 | 1.300 |
Why?
|
| Neoplasm, Residual | 5 | 2020 | 996 | 1.180 |
Why?
|
| Pathology, Surgical | 1 | 2022 | 149 | 0.830 |
Why?
|
| Specimen Handling | 3 | 2017 | 695 | 0.640 |
Why?
|
| Pathology | 2 | 2017 | 271 | 0.610 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 208 | 0.490 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 988 | 0.490 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2020 | 3555 | 0.410 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 288 | 0.380 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 667 | 0.370 |
Why?
|
| Receptor, erbB-2 | 8 | 2018 | 2331 | 0.370 |
Why?
|
| Adenofibroma | 1 | 2008 | 25 | 0.360 |
Why?
|
| Lymph Nodes | 4 | 2018 | 3433 | 0.350 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 1340 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 11317 | 0.280 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2008 | 347 | 0.270 |
Why?
|
| Breast | 2 | 2018 | 1820 | 0.270 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 537 | 0.260 |
Why?
|
| Immunohistochemistry | 9 | 2020 | 11766 | 0.260 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2018 | 1102 | 0.240 |
Why?
|
| Ovarian Neoplasms | 4 | 2017 | 4737 | 0.230 |
Why?
|
| Tumor Burden | 3 | 2019 | 1914 | 0.220 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 8016 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2018 | 916 | 0.220 |
Why?
|
| Receptors, Estrogen | 7 | 2018 | 2173 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7480 | 0.210 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 67 | 0.210 |
Why?
|
| Phyllodes Tumor | 1 | 2020 | 54 | 0.200 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 11192 | 0.200 |
Why?
|
| Angiomatosis | 1 | 2020 | 49 | 0.200 |
Why?
|
| Mastectomy, Segmental | 2 | 2017 | 945 | 0.200 |
Why?
|
| Receptors, Progesterone | 4 | 2021 | 1119 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1008 | 0.190 |
Why?
|
| Prognosis | 7 | 2021 | 29168 | 0.180 |
Why?
|
| Carcinoma | 2 | 2021 | 2325 | 0.180 |
Why?
|
| Female | 39 | 2023 | 377334 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 3705 | 0.160 |
Why?
|
| Carcinoma, Lobular | 3 | 2017 | 492 | 0.160 |
Why?
|
| Breast Diseases | 1 | 2020 | 444 | 0.150 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2017 | 121 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 4028 | 0.150 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 138 | 0.150 |
Why?
|
| Microscopy | 2 | 2019 | 873 | 0.140 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 372 | 0.140 |
Why?
|
| Humans | 43 | 2023 | 715124 | 0.140 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 19499 | 0.130 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2016 | 208 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 8925 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2020 | 62186 | 0.130 |
Why?
|
| CpG Islands | 1 | 2018 | 1158 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 469 | 0.120 |
Why?
|
| Curettage | 1 | 2013 | 71 | 0.120 |
Why?
|
| Lymphocyte Subsets | 1 | 2014 | 327 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2022 | 2579 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 644 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 2655 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 699 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 820 | 0.110 |
Why?
|
| Mesothelioma | 1 | 2017 | 814 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 775 | 0.100 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 3777 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2016 | 1019 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2013 | 500 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2011 | 136 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2017 | 983 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 1046 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1900 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 993 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 278 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3695 | 0.080 |
Why?
|
| Middle Aged | 17 | 2018 | 214871 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1996 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2018 | 4085 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 2971 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3071 | 0.080 |
Why?
|
| Databases, Genetic | 1 | 2013 | 1799 | 0.070 |
Why?
|
| Cell Differentiation | 4 | 2019 | 11746 | 0.070 |
Why?
|
| Aged | 15 | 2018 | 162674 | 0.070 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2005 | 67 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 1273 | 0.070 |
Why?
|
| Connecticut | 2 | 2017 | 365 | 0.070 |
Why?
|
| Cartilage | 1 | 2009 | 806 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 2075 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 15258 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 124 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 354 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2011 | 2443 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8674 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2017 | 2264 | 0.060 |
Why?
|
| Keratins | 1 | 2005 | 531 | 0.060 |
Why?
|
| Adult | 13 | 2018 | 212129 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2016 | 2950 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 2741 | 0.060 |
Why?
|
| Internet | 1 | 2016 | 3078 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2007 | 2412 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2713 | 0.060 |
Why?
|
| Pandemics | 1 | 2022 | 7213 | 0.060 |
Why?
|
| Albumins | 2 | 2016 | 567 | 0.060 |
Why?
|
| Biopsy | 3 | 2019 | 6750 | 0.060 |
Why?
|
| Decision Making | 1 | 2015 | 3828 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2007 | 890 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2022 | 294 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 34394 | 0.050 |
Why?
|
| Mastectomy | 3 | 2020 | 1703 | 0.050 |
Why?
|
| Phenotype | 2 | 2017 | 16371 | 0.050 |
Why?
|
| Research Design | 1 | 2015 | 5876 | 0.050 |
Why?
|
| Melanoma | 1 | 2017 | 5274 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 4924 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 3702 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5312 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 12567 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 97 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 375 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 58505 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2013 | 13292 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2018 | 199 | 0.040 |
Why?
|
| Paclitaxel | 2 | 2016 | 1674 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2001 | 1494 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 257 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 319 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2020 | 1173 | 0.040 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 77 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 812 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 8804 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 6371 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 5098 | 0.040 |
Why?
|
| Reoperation | 2 | 2017 | 4174 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2018 | 339 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 1623 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2007 | 8042 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2018 | 3319 | 0.030 |
Why?
|
| Macrophages | 2 | 2022 | 5805 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 683 | 0.030 |
Why?
|
| Rhode Island | 1 | 2014 | 360 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1632 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2680 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1594 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1607 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 2583 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 684 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 751 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 13268 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 2181 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 18345 | 0.030 |
Why?
|
| Monkey Diseases | 1 | 2011 | 79 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 17395 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 803 | 0.030 |
Why?
|
| Telomere | 1 | 2016 | 829 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2015 | 998 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2020 | 72255 | 0.030 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9521 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39285 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 7051 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 2529 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 2668 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2020 | 51181 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4320 | 0.020 |
Why?
|
| Axilla | 1 | 2009 | 540 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2027 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5333 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 1544 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4910 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2017 | 2114 | 0.020 |
Why?
|
| Liver | 1 | 2001 | 7647 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3460 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 16943 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5897 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2862 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2019 | 7836 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2009 | 771 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2005 | 193 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5238 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13732 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 630 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14877 | 0.010 |
Why?
|
| Animals | 4 | 2022 | 170726 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8738 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4918 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2022 | 12047 | 0.010 |
Why?
|
| Software | 1 | 2016 | 4350 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13302 | 0.010 |
Why?
|
| Anxiety | 1 | 2015 | 3898 | 0.010 |
Why?
|
| Proteomics | 1 | 2014 | 3256 | 0.010 |
Why?
|
| Microscopy, Atomic Force | 1 | 2001 | 252 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18789 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2018 | 21790 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2906 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 12425 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2007 | 1289 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3687 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 3010 | 0.010 |
Why?
|
| African Americans | 1 | 2013 | 5065 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2014 | 39804 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 2020 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23511 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 80995 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 2815 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 56155 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10531 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 41081 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 23973 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 29442 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 84999 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 8093 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 25090 | 0.000 |
Why?
|
| Male | 1 | 2001 | 351081 | 0.000 |
Why?
|